Earnings call transcript: Elekta Q4 2026 sees mixed results, stock drops 14%

Elekta’s Q4 was mixed: adjusted EBIT improved to SEK 902 million with an 18.9% margin and gross margin reached 39.9%, but net sales fell 1% in constant currency and reported EBIT swung to a SEK 461 million loss due to SEK 1.4 billion of one-time charges. Management guided to higher constant-currency sales and better EBIT margin in FY2026/2027, while also flagging continued FX, tariff, APAC, and Middle East headwinds. The stock fell 14.16% pre-market as investors focused on missed revenue and the large comparability items.

Analysis

The market is reacting to the wrong part of the print. The one-off charges are ugly, but the more important signal is that management is now forcefully engineering a cleaner revenue-quality profile: tighter order acceptance, shorter backlog duration, and lower capitalization/amortization mismatch. That usually hurts reported growth for a few quarters, but it improves the probability that the next 2-3 quarters of bookings convert into visible sales rather than another backlog haircut.

The second-order effect is that Elekta is trying to reset expectations around mix and cadence, not just margins. If they truly force more annual service renewals and higher upfront qualification on solution orders, near-term book-to-bill can look worse while future revenue becomes more predictable; that tends to compress the “growth at any price” multiple, but it also reduces the market’s discount rate on earnings quality. The key tell is whether APAC and the Middle East stabilize, because those regions are where a discipline-first policy can most easily mask underlying demand softness.

Competitively, this is potentially good for higher-quality rivals that can monetize service more cleanly and tolerate slower installs, because Elekta’s self-imposed order discipline may cede some low-quality share in the next 1-2 quarters. But if management is right that U.S. reimbursement pressure helps rather than hurts their installed-base economics, the company could emerge with better pricing power and a healthier replacement cycle than the market is assuming. The real catalyst is the June 17 CMD: if they pair a credible mid-term target with evidence that current savings are structural, the post-earnings drawdown can partially retrace.

Consensus is likely over-fixated on the reported EBIT shock and underestimating the balance-sheet cleanup’s value. The cleaner setup is to think of this as a low-quality quarter that improves future comparability; if the operating model savings persist, the next leg is not multiple expansion on growth, but multiple stabilization on cash conversion and dividend durability.

Key Decisions for Investors

• Long Elekta after the CMD only if management shows 2026/27 constant-currency growth plus stable FCF conversion; use a staggered entry because the near-term path can stay volatile while backlog quality normalizes.
• Sell rips in high-beta medtech proxies if Elekta’s CMD confirms disciplined order intake across the group; the setup favors lower top-line but better cash conversion, which can pressure names priced for faster growth.
• Pair trade: long Elekta / short a weaker European medtech peer with similar mix but less balance-sheet flexibility, targeting a 2-3 month window into CMD and the next quarter as quality-of-earnings rerates.
• If you want event convexity, buy a near-dated call spread on Elekta into the June 17 CMD; upside comes from a “less bad than feared” guide, while downside is bounded if the market remains focused on one-offs.
• Avoid chasing the post-print selloff as a standalone short: once the impairment overhang is digested, the stock can mean-revert on dividend support and cash-flow improvement over the next 1-2 quarters.